Improved Outcome of a Pediatric-Inspired Protocol for High-Risk Adolescent and Young Adult Acute Lymphoblastic Leukemia Patients Using Peg-Asparaginase and Escalating Dose of Methotrexate: Tolerability and Outcome
ConclusionThe use of a pediatric-inspired protocol for high-risk AYA ALL patients was effective and well tolerated with improvement in OS and DFS compared with historical data using adult protocols in such populations.
This case series demonstrates that cytoreductive surgery for diffused peritoneal metastases from lung cancer can yield improved prognosis and long-term survival.Journal of Medical Case Reports
SAN FRANCISCO - A groundskeeper whose $289 million award against Monsanto Co. was ultimately reduced to $78 million in his glyphosate cancer lawsuit filed a brief on Sept. 30 in a California appeals court contending that the court should disregard the attempts of various amici curiae to "inappropriately inject" new arguments and issues into the appeal (DeWayne Johnson v. Monsanto Company, Nos. A155940 and A156706, Calif. App., 1st Dist.).
SAN FRANCISCO - Monsanto Co. on Sept. 30 filed a brief in California appellate court contending that the U.S. Environmental Protection Agency has determined that glyphosate, the active ingredient in the herbicide Roundup, is not likely to cause cancer and, therefore, Roundup would be "misbranded" if it included a cancer warning (DeWayne Johnson v. Monsanto Company, Nos. A155940 and A156706, Calif. App, 1st Dist.).
SAN FRANCISCO - The circuit mediator for the Ninth Circuit U.S. Court of Appeals on Oct. 4 released from the mediation program two glyphosate cases against Monsanto Co. in which a cancer victim is appealing a district court judge's reduction of his original damages award against the company. Monsanto is cross-appealing the district court's denial of its motion for judgment notwithstanding the verdict (JNOV) (Edwin Hardeman v. Monsanto Company, No. 19-16636, 9th Cir.).
ConclusionThe use of pediatric-inspired protocol for high risk AYA ALL was effective and well tolerated with improvement in OS and DFS compared to historical data using adult protocols in such population
Treatment of acute lymphoblastic leukemia (ALL) in adolescent and young adult (AYA) patients using traditional adult chemotherapy protocols give low overall survival (OS) rates. The purpose of this prospective study was to assess efficacy and tolerability of treatment of AYA patients using a pediatric-inspired protocol modified from the Children ’s Cancer Group 1900 protocol for newly diagnosed high-risk Philadelphia chromosome-negative ALL patients. Forty patients with a median age of 18 years (range, 14-34 years) were enrolled in the study. Treatment was effective with a complete remission rate after induction of 9...
This study proposed a pilot study of a new tool for a reliable and accurate stratification of patients with acute leukemia based on an integrative model of leukemia behavior, cell characterization, and clinical features, in addition, to an evaluation of intra-tumor and inter-tumor heterogeneity. Together our approach allows us to introduce an integrative quantitative approach to use zebrafish and tumor characterization as a prediction tool for the behavior of acute leukemia in young adults. Materials and Methods Animal Care and Handling Zebrafish wild-type (A/B and TAB5) adults were raised and maintained according to st...
Curry J, Featherston S, Foglesong J, Shoberu B, Gulbis A, Mireles ME, Hafemeister L, Nguyen C, Kapoor N, Rezvani K, Neelapu SS, Shpall EJ, Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) Network Abstract In 2017, an autologous chimeric antigen receptor (CAR) T cell therapy indicated for children and young adults with relapsed and/or refractory CD19+ acute lymphoblastic leukaemia became the first gene therapy to be approved in the USA. This innovative form of cellular immunotherapy has been associated with remarkable response rates but is also associated with unique and often severe toxicities, which ...
Survival improvement in the AYA population has lagged behind that of younger patients. One contributing factor could be differences in drug metabolism and tolerance of cancer treatment. Previous studies have documented greater vincristine-related neurotoxicity (VRNT) in AYA vs. younger patients. One limitation of these studies is that age, rather than a more physiological assessment of developmental maturity, was used for the comparison.
Conclusion Insurance status and marriage did not influence outcomes for AYA with ALL, suggesting that intrinsic differences in disease and disease-specific therapies are more important than social issues. Micro-Abstract Outcomes for adolescents and young adults with acute lymphoblastic leukemia are worse when treated with adult rather than pediatric protocols; one criticism is that this may be due to “emancipation” of young adults. Population based review did not show marital and insurance status to be predictive of medial overall survival while age was.